Cellectar Biosciences, Inc. Profile Avatar - Palmy Investing

Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), whic…

Biotechnology
US, Florham Park [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Cellectar Biosciences, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of CLRB's Analysis
CIK: 1279704 CUSIP: 15117F500 ISIN: US15117F8077 LEI: - UEI: -
Secondary Listings
CLRB has no secondary listings inside our databases.